| Trial ID: | L6947 |
| Source ID: | NCT05226897
|
| Associated Drug: |
Yyc405-T
|
| Title: |
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: YYC405-T|DRUG: Metforminâ„1000mg|DRUG: Dapagliflozin 10mg|DRUG: YYC405-T placebo
|
| Outcome Measures: |
Primary: HbA1c, Change from baseline in Glycosylated Hemoglobin (HbA1c), Baseline, 24 weeks | Secondary: HbA1c, Change from baseline in Glycosylated Hemoglobin (HbA1c), Baseline, 12weeks|FPG, Fasting insulin, Change from baseline in Fasing plasma glucose and Fasting insulin, Baseline, 12weeks, 24weeks|C-peptide, Change from baseline in C-peptide, Baseline, 12weeks, 24weeks
|
| Sponsor/Collaborators: |
Sponsor: Yooyoung Pharmaceutical Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
256
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2021-07-12
|
| Completion Date: |
2023-06-26
|
| Results First Posted: |
|
| Last Update Posted: |
2022-06-01
|
| Locations: |
The Catholic University of Korea(Bucheon St. Mary's Hospital), Bucheon, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05226897
|
